Question 1

Can hydroxyzine replace benzodiazepines for acute anxiety without the addiction risk?

Accepted Answer

Hydroxyzine is a first-generation H1 antihistamine with FDA approval for anxiety. It has no dependence potential, no abuse liability, and no tolerance to the anxiolytic effect—making it a genuinely safer alternative to benzodiazepines in substance-use-vulnerable populations. However, it is measurably weaker: in the Hidalgo et al. (2007) meta-analysis, hydroxyzine's effect size was d=0.45, compared to benzodiazepines at d=0.38—a difference that is not clinically significant and positions the two classes closer than often assumed. The practical distinction is onset (30-60 minutes vs 15-30 minutes) and dependence risk, not raw efficacy. The Llorca et al. (2002) RCT found hydroxyzine non-inferior to bromazepam for GAD with lower rebound anxiety on discontinuation. Guidelines list hydroxyzine as second-line for GAD. The main clinical trade-off is safety for speed: hydroxyzine works adequately for mild-to-moderate situational anxiety and for patients with active substance use disorder, but its slower onset limits utility for acute panic. QTc prolongation risk exists at higher doses, and the 2023 AGS Beers Criteria lists hydroxyzine as inappropriate for adults over 65 due to anticholinergic burden.

Question 2

How does hydroxyzine's onset compare to benzodiazepines?

Accepted Answer

Hydroxyzine is a first-generation H1 antihistamine with FDA approval for anxiety. It has no dependence potential, no abuse liability, and no tolerance to the anxiolytic effect—making it a genuinely safer alternative to benzodiazepines in substance-use-vulnerable populations. However, it is measurably weaker: in the Hidalgo et al. (2007) meta-analysis, hydroxyzine's effect size was d=0.45, compared to benzodiazepines at d=0.38—a difference that is not clinically significant and positions the two classes closer than often assumed. The practical distinction is onset (30-60 minutes vs 15-30 minutes) and dependence risk, not raw efficacy. The Llorca et al. (2002) RCT found hydroxyzine non-inferior to bromazepam for GAD with lower rebound anxiety on discontinuation. Guidelines list hydroxyzine as second-line for GAD. The main clinical trade-off is safety for speed: hydroxyzine works adequately for mild-to-moderate situational anxiety and for patients with active substance use disorder, but its slower onset limits utility for acute panic. QTc prolongation risk exists at higher doses, and the 2023 AGS Beers Criteria lists hydroxyzine as inappropriate for adults over 65 due to anticholinergic burden.

Question 3

What's the evidence for hydroxyzine efficacy vs benzodiazepines?

Accepted Answer

Hydroxyzine is a first-generation H1 antihistamine with FDA approval for anxiety. It has no dependence potential, no abuse liability, and no tolerance to the anxiolytic effect—making it a genuinely safer alternative to benzodiazepines in substance-use-vulnerable populations. However, it is measurably weaker: in the Hidalgo et al. (2007) meta-analysis, hydroxyzine's effect size was d=0.45, compared to benzodiazepines at d=0.38—a difference that is not clinically significant and positions the two classes closer than often assumed. The practical distinction is onset (30-60 minutes vs 15-30 minutes) and dependence risk, not raw efficacy. The Llorca et al. (2002) RCT found hydroxyzine non-inferior to bromazepam for GAD with lower rebound anxiety on discontinuation. Guidelines list hydroxyzine as second-line for GAD. The main clinical trade-off is safety for speed: hydroxyzine works adequately for mild-to-moderate situational anxiety and for patients with active substance use disorder, but its slower onset limits utility for acute panic. QTc prolongation risk exists at higher doses, and the 2023 AGS Beers Criteria lists hydroxyzine as inappropriate for adults over 65 due to anticholinergic burden.

Question 4

Is hydroxyzine appropriate for PRN situational anxiety?

Accepted Answer

Hydroxyzine is a first-generation H1 antihistamine with FDA approval for anxiety. It has no dependence potential, no abuse liability, and no tolerance to the anxiolytic effect—making it a genuinely safer alternative to benzodiazepines in substance-use-vulnerable populations. However, it is measurably weaker: in the Hidalgo et al. (2007) meta-analysis, hydroxyzine's effect size was d=0.45, compared to benzodiazepines at d=0.38—a difference that is not clinically significant and positions the two classes closer than often assumed. The practical distinction is onset (30-60 minutes vs 15-30 minutes) and dependence risk, not raw efficacy. The Llorca et al. (2002) RCT found hydroxyzine non-inferior to bromazepam for GAD with lower rebound anxiety on discontinuation. Guidelines list hydroxyzine as second-line for GAD. The main clinical trade-off is safety for speed: hydroxyzine works adequately for mild-to-moderate situational anxiety and for patients with active substance use disorder, but its slower onset limits utility for acute panic. QTc prolongation risk exists at higher doses, and the 2023 AGS Beers Criteria lists hydroxyzine as inappropriate for adults over 65 due to anticholinergic burden.

PsychHQ

Hydroxyzine for Acute Anxiety: Can It Replace Benzodiazepines Without the Addiction Risk?